Autoimmune markers in diabetes

Clinical Chemistry

Volumn 57, Issue 2, 2011, Pages 168-175

  Winter, William E ^a,b   Schatz, Desmond A ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

51 KDA AROMATIC LEVO AMINO ACID DECARBOXYLASE AUTOANTIBODY; 52 KDA RIN AUTOANTIBODY; AMINOACYL TRNA SYNTHETASE AUTOANTIBODY; AUTOANTIBODY; AUTOANTIBODY CARBONIC ANHYDRASE 2; AUTOANTIBODY CARBOXYPEPTIDASE H; AUTOANTIBODY IAA; CHYMOTRYPSINOGEN RELATED 30 KDA PANCREATIC AUTOANTIBODY; DNA TOPOISOMERASE 2 AUTOANTIBODY; GADA AUTOANTIBODY; GLIMA 38 AUTOANTIBODY; GLUT2 AUTOANTIBODY; GLYCOLIPID AUTOANTIBODY; GM2 1 ISLET GANGLIOSIDE AUTOANTIBODY; HEAT SHOCK PROTEIN AUTOANTIBODY; IA 2 BETA AUTOANTIBODY; IA 2A AUTOANTIBODY; ICA AUTOANTIBODY; ISLET CELL SPECIFIC 38 KDA AUTOANTIBODY; ISLET CELL SURFACE AUTOANTIBODY; PROINSULIN AUTOANTIBODY; RITUXIMAB; UNCLASSIFIED DRUG; ZNT8A AUTOANTIBODY;

AUTOIMMUNITY; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; DIABETES MELLITUS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REVIEW;

ANIMALS; AUTOANTIBODIES; B-LYMPHOCYTES; BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 1; HUMANS; ISLETS OF LANGERHANS; RISK FACTORS;

EID: 79551470267     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2010.148205     Document Type: Review

References (81)

1. Michels AW, Eisenbarth GS. Immunologic endocrine disorders. J Allergy Clin Immunol 2010;125(2 Suppl 2):S226-37.
2. Peng H, Hagopian W. Environmental factors in the development of Type 1 diabetes. Rev Endocr Metab Disord 2006;7:149-62. (Pubitemid 46084826)
3. Concannon P, Rich SS, Nepom GT. Genetics of type 1A diabetes. N Engl J Med 2009;360:1646-54.
4. Miao D, Yu L, Eisenbarth GS. Role of autoantibodies in type 1 diabetes. Front Biosci 2007;12:1889-98.
5. Jahromi MM, Eisenbarth GS. Cellular and molecular pathogenesis of type 1A diabetes. Cell Mol Life Sci 2007;64:865-72.
6. Hummel M, Bonifacio E, Schmid S, Walter M, Knopff A, Ziegler AG. Brief communication: early appearance of islet autoantibodies predicts childhood type 1 diabetes in offspring of diabetic parents. Ann Intern Med 2004;140:882-6.
7. TEDDY Study Group. The Environmental Determinants of Diabetes in the Young (TEDDY) Study. Ann NY Acad Sci 2008;1150:1-13.
8. Wong FS, Wen L. B cells in autoimmune diabetes. Rev Diabet Stud 2005;2:121-35.
9. von Boehmer H, Melchers F. Checkpoints in lymphocyte development and autoimmune disease. Nat Immunol 2010;11:14-20.
10. Yoon JW, Jun HS. Autoimmune destruction of pancreatic beta cells. Am J Ther 2005;12:580-91.
11. Sperling MA. The genetic basis of neonatal diabetes mellitus. Pediatr Endocrinol Rev 2006;(4 Suppl 1):71-5.
12. Gach A, Wyka K, Malecki MT, Noczynska A, Skupien J, Nazim J, et al. Islet-specific antibody seroconversion in patients with long duration of permanent neonatal diabetes caused by mutations in the KCNJ11 gene. Diabetes Care 2007;30:2080-2.
13. Christen U, Hintermann E, Holdener M, von Herrath MG. Viral triggers for autoimmunity: is the "glass of molecular mimicry" half full or half empty? J Autoimmun 2010;34:38-44.
14. Yang L, Zhou ZG, Tan SZ, Huang G, Jin P, Yan X, et al. Carboxypeptidase-H autoantibodies differentiate a more latent subset of autoimmune diabetes from phenotypic type 2 diabetes among Chinese adults. Ann NY Acad Sci 2008;1150:263-6.
15. Palmer JP, Asplin CM, Clemons P, Lyen K, Tatpati O, Raghu PK, Paquette TL. Insulin antibodies in insulin-dependent diabetics before insulin treatment. Science (Wash DC) 1983;222:1337-9.
16. Kuglin B, Halder B, Bertrams J, Grüneklee D, Gries FA, Kolb H. Proinsulin autoantibodies: association with type I diabetes but not with islet cell antibodies, insulin autoantibodies or HLA-DR type. J Autoimmun 1990;3:573-7.
17. Wenzlau JM, Moua O, Sarkar SA, Yu L, Rewers M, Eisenbarth GS, et al. SlC30A8 is a major target of humoral autoimmunity in type 1 diabetes and a predictive marker in prediabetes. Ann NY Acad Sci 2008;1150:256-9.
18. Verge CF, Gianani R, Kawasaki E, Yu L, Pietropaolo M, Jackson RA, et al. Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes 1996;45:926-33.
19. Kawasaki E, Hutton JC, Eisenbarth GS. Molecular cloning and characterization of the human transmembrane protein tyrosine phosphatase homologue, phogrin, an autoantigen of type 1 diabetes. Biochem Biophys Res Commun 1996;227:440-7.
20. Taniguchi T, Okazaki K, Okamoto M, Seko S, Uchida K, Seino Y. Presence of autoantibodies to carbonic anhydrase II and lactoferrin in type 1 diabetes: proposal of the concept of autoimmune exocrinopathy and endocrinopathy of the pancreas. Diabetes Care 2001;24:1695-6.
21. Kim YJ, Zhou Z, Hurtado J, Wood DL, Choi AS, Pescovitz MD, et al. IDDM patients' sera recognize a novel 30-kD pancreatic autoantigen related to chymotrypsinogen. Immunol Invest 1993;22:219-27.
22. Chang YH, Hwang J, Shang HF, Tsai ST. Characterization of human DNA topoisomerase II as an autoantigen recognized by patients with IDDM. Diabetes 1996;45:408-14.
23. Baekkeskov S, Aanstoot HJ, Christgau S, Reetz A, Solimena M, Cascalho M, et al. Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature 1990;347:151-6.
24. Rorsman F, Husebye ES, Winqvist O, Bjork E, Karlsson FA, Kampe O. Aromatic-L-amino-acid decarboxylase, a pyridoxal phosphate-dependent enzyme, is a beta-cell autoantigen. Proc Natl Acad Sci USA 1995;92:8626-9.
25. Park SG, Park HS, Jeong IK, Cho YM, Lee HK, Kang YS, et al. Autoantibodies against aminoacyl-tRNA synthetase: novel diagnostic marker for type 1 diabetes mellitus. Biomarkers 2010;15:358-66.
26. Aanstoot HJ, Kang SM, Kim J, Lindsay LA, Roll U, Knip M, et al. Identification and characterization of glima 38, a glycosylated islet cell membrane antigen, which together with GAD65 and IA2 marks the early phases of autoimmune response in type 1 diabetes. J Clin Invest 1996;97:2772-83.
27. Johnson JH, Crider BP, McCorkle K, Alford M, Unger RH. Inhibition of glucose transport into rat islet cells by immunoglobulins from patients with new-onset insulin-dependent diabetes mellitus. N Engl J Med 1990;332:653-9.
28. Cabrera-Rode E, Diaz-Horta O, Fernandez LE, Carr A, Marquina G, Valiente O, et al. Glycolipids as the major autoantigens of cytoplasmatic islet cell antibodies. Autoimmunity 1995;20:145-51.
29. Dotta F, Falorni A, Tiberti C, Dionisi S, Anastasi E, Torresi P, et al. Autoantibodies to the GM2-1 islet ganglioside and to GAD-65 at type 1 diabetes onset. J Autoimmun 1997;10:585-8.
30. Jones DB, Hunter NR, Duff GW. Heat-shock protein 65 as a beta cell antigen of insulindependent diabetes. Lancet 1990;8336:583-5.
31. Maclaren NK, Huang SW, Fogh J. Antibody to cultured human insulinoma cells in insulin-dependent diabetes. Lancet 1975;1:997-1000.
32. Bottazzo GF, Florin-Christensen A, Doniach D. Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet 1974;2:1279-83.
33. Pak CY, Cha CY, Rajotte RV, McArthur RG, Yoon JW. Human pancreatic islet cell specific 38 kilodalton autoantigen identified by cytomegalovirus induced monoclonal islet cell autoantibody. Diabetologia 1990;33:569-72.
34. Karounos DG, Thomas JW. Recognition of common islet antigen by autoantibodies from NOD mice and humans with IDDM. Diabetes 1990;39:1085-90.
35. Zhang L, Nakayama M, Eisenbarth GS. Insulin as an autoantigen in NOD/human diabetes. Curr Opin Immunol 2008;20:111-8.
36. Pugliese A, Zeller M, Fernandez A Jr, Zalcberg LJ, Bartlett RJ, Ricordi C, et al. The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes. Nat Genet 1997;15:293-7.
37. Csorba TR, Lyon AW, Hollenberg MD. Autoimmunity and the pathogenesis of type 1 diabetes. Crit Rev Clin Lab Sci 2010;47:51-71.
38. Diabetes Prevention Trial-Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 2002;346:1685-91.
39. Levy-Marchal C, Bridel MP, Sodoyez-Goffaux F, Koch M, Tichet J, Czernichow P, Sodoyez JC. Superiority of radiobinding assay over ELISA for detection of IAAs in newly diagnosed type I diabetic children. Diabetes Care 1991;14:61-3.
40. Borowiec M, Thompson R, Powers C, Xu R, Dickey T, Doria A. Mutations in the SLC30A8 gene are not a major cause of MODY or other forms of early-onset, autosomal dominant type 2 diabetes. Diabetologia 2007;50:2224-6.
41. Reddy S, Wu D, Poole CA. Glutamic acid decarboxylase 65 and 67 isoforms in fetal, neonatal and adult porcine islets: predominant beta cell co-localization by light and confocal microscopy. J Autoimmun 1996;9:21-7.
42. Zimmet PZ, Tuomi T, Mackay IR, Rowley MJ, Knowles W, Cohen M, Lang DA. Latent autoimmune diabetes mellitus in adults (LADA): the role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency. Diabet Med 1994;11:299-303.
43. Gianani R, Rabin DU, Verge CF, Yu L, Babu SR, Pietropaolo M, Eisenbarth GS. ICA512 autoantibody radioassay. Diabetes 1995;44:1340-4.
44. Libman IM, Pietropaolo M, Trucco M, Dorman JS, LaPorte RE, Becker D. Islet cell autoimmunity in white and black children and adolescents with IDDM. Diabetes Care 1998;21:1824-7.
45. Winter WE, Harris N, Schatz D. Immunologic markers in the diagnosis, and prediction of autoimmune, type 1A diabetes. Clinical Diabetes 2002;20:183-91.
46. Winter WE, Harris N, Schatz D. Type 1 diabetes islet autoantibody markers. Diabetes Technol Ther 2002;4:817-39.
47. Orban T, Sosenko JM, Cuthbertson D, Krischer JP, Skyler JS, Jackson R, et al. Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2009;32:2269-74.
48. Schatz D, Krischer J, Horne G, Riley W, Spillar R, Silverstein J, et al. Islet cell antibodies predict insulin-dependent diabetes in United States school age children as powerfully as in unaffected relatives. J Clin Invest 1994;93:2403-7.
49. Kimpimäki T, Kulmala P, Savola K, Kupila A, Korhonen S, Simell T, et al. Natural history of beta-cell autoimmunity in young children with increased genetic susceptibility to type 1 diabetes recruited from the general population. J Clin Endocrinol Metab 2002;87:4572-9.
50. Lichten LA, Cousins RJ. Mammalian zinc transporters: nutritional and physiologic regulation. Annu Rev Nutr 2009;29:153-76.
51. Chimienti F, Devergnas S, Favier A, Seve M. Identification and cloning of a beta-cell-specific zinc transporter, ZnT-8, localized into insulin secretory granules. Diabetes 2004;53:2330-7.
52. Sladek R, Rocheleau G, Rung J, Dina C, Shen L, Serre D, Boutin P, et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature. 2007;22:445:881-5.
53. Wenzlau JM, Juhl K, Yu L, Moua O, Sarkar SA, Gottlieb P, et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci U S A 2007;104:17040-5.
54. Wenzlau JM, Walter M, Gardner TJ, Frisch LM, Yu L, Eisenbarth GS, et al. Kinetics of the post-onset decline in zinc transporter 8 autoantibodies in type 1 diabetic human subjects. J Clin Endocrinol Metab 2010;95:4712-9.
55. Vaziri-Sani F, Oak S, Radtke J, Lernmark A, Lynch K, Agardh CD, et al. ZnT8 autoantibody titers in type 1 diabetes patients decline rapidly after clinical onset. Autoimmunity. 2010;43:598-606.
56. Wenzlau JM, Liu Y, Yu L, Moua O, Fowler KT, Rangasamy S, et al. A common nonsynonymous single nucleotide polymorphism in the SLC30A8 gene determines ZnT8 autoantibody specificity in type 1 diabetes. Diabetes 2008;57:2693-7.
57. Achenbach P, Lampasona V, Landherr U, Koczwara K, Krause S, Grallert H, et al. Autoantibodies to zinc transporter 8 and SLC30A8 genotype stratify type 1 diabetes risk. Diabetologia 2009;52:1881-8.
58. Leslie RD, Kolb H, Schloot NC, Buzzetti R, Mauricio D, De Leiva A, et al. Diabetes classification: grey zones, sound and smoke: Action LADA 1. Diabetes Metab Res Rev 2008;24:511-9.
59. Irvine WJ, McCallum CJ, Gray RS, Duncan LJ. Clinical and pathogenic significance of pancreaticislet-cell antibodies in diabetics treated with oral hypoglycaemic agents. Lancet 1977;1:1025-7.
60. Winter WE, Chihara T, Schatz DA. The genetics of autoimmune diabetes: approaching a solution to the problem. Am J Dis Child 1993;147:1282-90.
61. Isermann B, Ritzel R, Zorn M, Schilling T, Nawroth PP. Autoantibodies in diabetes mellitus: current utility and perspectives. Exp Clin Endocrinol Diabetes 2007;115:483-90.
62. Shah SC, Malone JI, Simpson NE. A randomized trial of intensive insulin therapy in newly diagnosed insulin-dependent diabetes mellitus. N Engl J Med 1989;320:550-4.
63. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
64. Silveira PA, Grey ST. B cells in the spotlight: innocent bystanders or major players in the pathogenesis of type 1 diabetes. Trends Endocrinol Metab 2006;17:128-35.
65. Yanaba K, Bouaziz JD, Matsushita T, Magro CM, St Clair EW, Tedder TF. B-lymphocyte contributions to human autoimmune disease. Immunol Rev 2008;223:284-99.
66. Manjarrez-Orduño N, Quách TD, Sanz N. B cells and immunological tolerance. J Invest Dermatol 2009;129:278-88.
67. Lund FE, Randall TD. Effector and regulatory B cells: modulators of CD4(+) T cell immunity. Nat Rev Immunol 2010;10:236-47.
68. Mauri C, Ehrenstein MR. The "short" history of regulatory B cells. Trends Immunol 2008;29:34-40.
69. Evans JG, Chavez-Rueda KA, Eddaoudi A, Meyer-Bahlburg A, Rawlings DJ, Ehrenstein MR, Mauri C. Novel suppressive function of transitional 2 B cells in experimental arthritis. J Immunol 2007;178:7868-78.
70. Martin S, Wolf-Eichbaum D, Duinkerken G, Scherbaum WA, Kolb H, Noordzij JG, Roep BO. Development of type 1 diabetes despite severe hereditary B-lymphocyte deficiency. N Engl J Med 2001;345:1036-40.
71. Young RJ, Duncan LJ, Paton L, Yap PL. Development of insulin-dependent diabetes in adultonset hypogammaglobulinaemia. Br Med J 1981;282:1668.
72. Moffitt JE, Guill MF, Leffell MS, Ades EW, Burek CL, Lobel SA, Hoffman WH. Type I diabetes in an adolescent with common variable immunodeficiency. J Allergy Clin Immunol 1989;84:191-6.
73. Kendall PL, Moore DJ, Hulbert C, Hoek KL, Khan WN, Thomas JW. Reduced diabetes in btkdeficient nonobese diabetic mice and restoration of diabetes with provision of an anti-insulin IgH chain transgene. J Immunol 2009;183:6403-12.
74. Xiu Y, Wong CP, Bouaziz JD, Hamaguchi Y, Wang Y, Pop SM, et al. B lymphocyte depletion by CD20 monoclonal antibody prevents diabetes in nonobese diabetic mice despite isotype-specific differences in Fc gamma R effector functions. J Immunol 2008;180:2863-75.
75. O'Neill SK, Liu E, Cambier JC. Change you can B(cell)eive in: recent progress confirms a critical role for B cells in type 1 diabetes. Curr Opin Endocrinol Diabetes Obes 2009;16:293-8.
76. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, Becker DJ, Gitelman SE, Goland R, et al. Type 1 Diabetes TrialNet Anti-CD20 Study Group. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009;361:2143-52.
77. Noorchashm H, Noorchashm N, Kern J, Rostami SY, Barker CF, Naji A. B-cells are required for the initiation of insulitis and sialitis in nonobese diabetic mice. Diabetes 1997;46:941-6.
78. Bingley PJ. Clinical applications of diabetes antibody testing. J Clin Endocrinol Metab 2010;95:25-33.
79. Pihoker C, Gilliam LK, Hampe CS, Lernmark A. Autoantibodies in diabetes. Diabetes 2005;54(Suppl 2):S52-61.
80. Näntö-Salonen K, Kupila A, Simell S, Siljander H, Salonsaari T, Hekkala et al. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial Lancet. 2008;372:1746-55.
81. Ludvigsson J, Faresjö M, Hjorth M, Axelsson S, Chéramy M, Pihl M, et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 2008;359:1909-20.